Abstract

IntroductionPatients with high grade serous ovarian carcinoma (HGSOC) who harbour BRCA1 and BRCA2 mutations respond better to PARP inhibitor treatment. BRCA mutations can be germline, somatic or both. Germline BRCA...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call